Equity Profile

RPRX

Royalty Pharma plc

Health CarePharmaceuticals$26.1B

Aug5Wed

Pre-Earnings Brief

UpcomingQ4-2017Pre-Market9:00 AM EDT

Company Snapshot

Royalty Pharma plc is a healthcare company that focuses on acquiring royalties from innovative biopharmaceutical products. With a market cap of $26 billion, it plays a significant role in the pharmaceutical industry by providing funding to drug developers while sharing in the revenue generated from their products.

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and revenues.

$1.18

Revenue

Total revenue reflects the company's ability to generate sales from its royalty agreements, which is crucial for its financial health.

$874M

Wall Street expectations, options signals, track record, and call prep available with Pro.

RPRX Q4-2017 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

13%

Avg EPS Surprise

+5.28%

Avg Stock Reaction

+0.00%

Last Quarter Recap

In the last quarter, Royalty Pharma reported an EPS of -$0.04, continuing a trend of losses. Revenue figures were not disclosed, but the company has faced challenges in meeting analyst expectations.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Royalty Pharma to report an EPS of $1.18 and revenue of $874 million, indicating a cautious optimism about its financial recovery.

Bull Case

If the company can exceed EPS expectations and show strong revenue growth, it may indicate a turnaround in profitability and investor confidence.

Bear Case

Conversely, if the company fails to meet these expectations, it could signal ongoing operational challenges and lead to further declines in stock price.

Key Metrics to Watch

EPS

$1.18

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and revenues.

Revenue

$874M

Total revenue reflects the company's ability to generate sales from its royalty agreements, which is crucial for its financial health.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will EPS exceed the consensus estimate of $1.18?

A positive surprise in EPS could indicate improved profitability and boost investor confidence.

What specific revenue figures can management provide?

Understanding revenue performance will be critical to assessing the company's financial health and growth prospects.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may be underestimating the potential for revenue growth given recent trends in the pharmaceutical sector, which could positively impact Royalty Pharma's earnings.

Supporting Evidence

The options market is pricing a significant move, indicating that investors expect volatility and potential surprises.

Historical data shows that the stock has reacted positively to earnings beats in the past, suggesting a potential for upside.

Key Risk

If revenue growth significantly exceeds $874 million, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Royalty Pharma can turn around its financial performance after a series of disappointing earnings.

Bull Confirmed If

Exceeding the EPS estimate of $1.18 and showing revenue growth above $874 million would confirm a bullish outlook.

Bear Confirmed If

Failing to meet the EPS estimate and reporting stagnant or declining revenue would reinforce bearish sentiment.

Pre-Earnings Positioning

Options Market

Implied Move

±12.33%

The options market is pricing in a significant move, suggesting that investors are anticipating volatility around the earnings announcement.

Detail

ATM IV

0.3%

30d HV

19.2%

Calls (25K)P/C Ratio: 0.01Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Mixed flows

Institutional

84.49%

of float

Insider

7.12%

of float

Holders

844

institutions

Top Holders· as of Dec 2025

Morgan Stanley
55,274,069 sh · $2.7B
12.44%
25.2%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Royalty Pharma beats expectations, history suggests the stock could rise by an average of 5.5%, confirming a positive trend.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

A miss could lead to a decline, with historical patterns indicating an average drop of around 2.1% in such scenarios.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new royalty agreements or acquisitions.
2Management's outlook on revenue growth for the upcoming quarters.
3Details on cost management strategies and their impact on profitability.
4Insights into market trends affecting the pharmaceutical sector.
5Any commentary on competitive pressures and how the company plans to address them.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and revenues.

$1.18

Revenue

Total revenue reflects the company's ability to generate sales from its royalty agreements, which is crucial for its financial health.

$874M

Wall Street expectations, options signals, track record, and call prep available with Pro.

RPRX Q4-2017 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

13%

Avg EPS Surprise

+5.28%

Avg Stock Reaction

+0.00%

Last Quarter Recap

In the last quarter, Royalty Pharma reported an EPS of -$0.04, continuing a trend of losses. Revenue figures were not disclosed, but the company has faced challenges in meeting analyst expectations.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Royalty Pharma to report an EPS of $1.18 and revenue of $874 million, indicating a cautious optimism about its financial recovery.

Bull Case

If the company can exceed EPS expectations and show strong revenue growth, it may indicate a turnaround in profitability and investor confidence.

Bear Case

Conversely, if the company fails to meet these expectations, it could signal ongoing operational challenges and lead to further declines in stock price.

Key Metrics to Watch

EPS

$1.18

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and revenues.

Revenue

$874M

Total revenue reflects the company's ability to generate sales from its royalty agreements, which is crucial for its financial health.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will EPS exceed the consensus estimate of $1.18?

A positive surprise in EPS could indicate improved profitability and boost investor confidence.

What specific revenue figures can management provide?

Understanding revenue performance will be critical to assessing the company's financial health and growth prospects.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may be underestimating the potential for revenue growth given recent trends in the pharmaceutical sector, which could positively impact Royalty Pharma's earnings.

Supporting Evidence

The options market is pricing a significant move, indicating that investors expect volatility and potential surprises.

Historical data shows that the stock has reacted positively to earnings beats in the past, suggesting a potential for upside.

Key Risk

If revenue growth significantly exceeds $874 million, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Royalty Pharma can turn around its financial performance after a series of disappointing earnings.

Bull Confirmed If

Exceeding the EPS estimate of $1.18 and showing revenue growth above $874 million would confirm a bullish outlook.

Bear Confirmed If

Failing to meet the EPS estimate and reporting stagnant or declining revenue would reinforce bearish sentiment.

Pre-Earnings Positioning

Options Market

Implied Move

±12.33%

The options market is pricing in a significant move, suggesting that investors are anticipating volatility around the earnings announcement.

Detail

ATM IV

0.3%

30d HV

19.2%

Calls (25K)P/C Ratio: 0.01Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Mixed flows

Institutional

84.49%

of float

Insider

7.12%

of float

Holders

844

institutions

Top Holders· as of Dec 2025

Morgan Stanley
55,274,069 sh · $2.7B
12.44%
25.2%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Royalty Pharma beats expectations, history suggests the stock could rise by an average of 5.5%, confirming a positive trend.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

A miss could lead to a decline, with historical patterns indicating an average drop of around 2.1% in such scenarios.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new royalty agreements or acquisitions.
2Management's outlook on revenue growth for the upcoming quarters.
3Details on cost management strategies and their impact on profitability.
4Insights into market trends affecting the pharmaceutical sector.
5Any commentary on competitive pressures and how the company plans to address them.